Date: 2014-10-27
Type of information: Resignation
Compound:
Company: Epizyme (USA - MA)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On October 27, 2014, Epizyme, a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced that Chief Medical Officer Eric Hedrick, M.D., has resigned from the Company, effective October 31, 2014. Dr. Hedrick has agreed to assist Epizyme in an advisory capacity through the end of 2014. Peter Ho, M.D., Ph.D., who joined the company in September as Chief Development Officer, will continue to oversee the Company’s clinical
development, regulatory and translational medicine functions. Dr. Ho’s prior experience includes positions as Vice President of Oncology Development at Johnson & Johnson and Senior Vice President, Oncology Center of Excellence for Drug Development at GSK. He received his board certification in pediatric hematology/oncology and was formerly a fellow at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) and the FD). Dr. Ho received a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. (pharmacology) from the Yale University School of Medicine.
Financial terms:
Latest news:
